Related Experiment Videos
The effect of VP 16-213 on NBT reduction in the normal polymorphonuclear neutrophil
Abstract:
VP 16-213, an antineoplastic, semisynthetic podophyllotoxin derivative, inhibits NBT reduction in the polymorphonuclear neutrophil (PMN). In the resting PMN an almost complete inhibition is seen at a concentration of 170 microM and a partial inhibition is seen at 17 microM. In PMN's stimulated with zymosan activated serum, partial inhibition is seen at concentrations of both 170 microM and 17 microM. VP 16-213 shows no significant inhibition of NBT reduction in PMN's stimulated by methylene blue. VP 16-213 may alter normal respiratory function in the PMN as reflected by inhibition of NBT reduction.
Insights
VP 16-213, a chemotherapy drug, inhibits nitroblue tetrazolium (NBT) reduction in polymorphonuclear neutrophils (PMNs). This suggests VP 16-213 may impact PMN respiratory function.
Area of Science:
- Pharmacology
- Immunology
- Cell Biology
Background:
- VP 16-213 is a semisynthetic podophyllotoxin derivative used as an antineoplastic agent.
- Polymorphonuclear neutrophils (PMNs) play a crucial role in the innate immune response.
- Nitroblue tetrazolium (NBT) reduction is a common assay to assess the oxidative burst activity of PMNs.
Purpose of the Study:
- To investigate the effect of VP 16-213 on NBT reduction in human PMNs.
- To determine if VP 16-213 modulates PMN respiratory function.
Main Methods:
- Assessing NBT reduction in resting and stimulated PMNs.
- Utilizing varying concentrations of VP 16-213 (17 microM and 170 microM).
- Stimulating PMNs with zymosan-activated serum and methylene blue.
Main Results:
- VP 16-213 demonstrated significant inhibition of NBT reduction in resting PMNs at both tested concentrations.
- Partial inhibition of NBT reduction was observed in PMNs stimulated with zymosan-activated serum.
- No significant inhibition was found in PMNs stimulated with methylene blue.
Conclusions:
- VP 16-213 inhibits NBT reduction in PMNs, indicating a potential impact on their respiratory function.
- The drug's effect varies depending on the PMN activation state.
- Further research is warranted to elucidate the precise mechanisms of VP 16-213 on PMN oxidative metabolism.